Document Detail


Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.
MedLine Citation:
PMID:  23045591     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers to stratify patients regarding recurrence risk and may inform treatment decisions. We tested the efficacy of this panel in the Tamoxifen versus Exemestane Adjuvant Multicenter (TEAM) trial.
PATIENTS AND METHODS: Pathology blocks from 4,598 TEAM patients were collected, and tissue microarrays (TMAs) were constructed. The cohort was 47% node-positive, and 36% of patients in the cohort were treated with adjuvant chemotherapy. Triplicate 0.6-mm(2) TMA cores were stained, and positivity for p53, HTF9C, CEACAM5, NDRG1, and SLC7A5 was assessed. Cases were assigned a Mammostrat risk score, and distant relapse-free survival (DRFS) and disease-free survival (DFS) were analyzed.
RESULTS: In multivariate regression analyses, which were corrected for conventional clinicopathologic markers, Mammostrat provided significant additional information on DRFS after endocrine therapy in estrogen receptor (ER) -positive node-negative patients (n = 1,226) who did not receive chemotherapy (P = .004). Additional analyses in all patients not exposed to chemotherapy, irrespective of nodal status (n = 2,559) and in the entire cohort (n = 3,837) showed Mammostrat scores provided additional information on DRFS in these groups (P = .001 and P < .001, respectively; multivariate analyses). No differences were seen between the two endocrine treatment regimens.
CONCLUSION: The Mammostrat score predicts DRFS for patients treated with exemestane and patients treated with tamoxifen followed by exemestane irrespective of nodal status and chemotherapy. The ability of this test to provide additional outcome data after treatment provides additional evidence of its use in risk stratification of ER-positive postmenopausal patients with breast cancer.
Authors:
John M S Bartlett; Kenneth J Bloom; Tammy Piper; Thomas J Lawton; Cornelis J H van de Velde; Douglas T Ross; Brian Z Ring; Robert S Seitz; Rodney A Beck; Annette Hasenburg; Dirk Kieback; Hein Putter; Christos Markopoulos; Luc Dirix; Caroline Seynaeve; Daniel Rea
Publication Detail:
Type:  Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-10-08
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  30     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-18     Completed Date:  2013-05-07     Revised Date:  2013-09-13    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4477-84     Citation Subset:  IM    
Affiliation:
Ontario Institute for Cancer Research, Toronto, Ontario, Canada. john.bartlett@oicr.on.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androstadienes / adverse effects,  therapeutic use*
Antineoplastic Agents / adverse effects,  therapeutic use
Antineoplastic Agents, Hormonal / adverse effects,  therapeutic use
Breast Neoplasms / drug therapy*,  genetics,  metabolism,  pathology*
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Immunohistochemistry
Neoplasms, Hormone-Dependent / drug therapy*,  genetics,  metabolism,  pathology*
Recurrence
Retrospective Studies
Risk Factors
Tamoxifen / adverse effects,  therapeutic use*
Tissue Array Analysis / methods*
Chemical
Reg. No./Substance:
0/Androstadienes; 0/Antineoplastic Agents; 0/Antineoplastic Agents, Hormonal; 10540-29-1/Tamoxifen; 107868-30-4/exemestane
Comments/Corrections
Comment In:
J Clin Oncol. 2013 Jul 20;31(21):2760-1   [PMID:  23775953 ]
J Clin Oncol. 2012 Dec 20;30(36):4451-3   [PMID:  23045595 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Validation of a Gene Expression Signature for Assessment of Lymph Node Metastasis in Oral Squamous C...
Next Document:  Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter stu...